Johnson & Johnson is a global healthcare company that develops and manufactures a wide range of products across three major segments: Pharmaceuticals, Medical Devices, and Consumer Health. Its core products include prescription medications, surgical instruments, and consumer health products such as over-the-counter drugs and personal care items. The company generates revenue primarily from its pharmaceutical segment, which includes treatments for various diseases, followed by medical devices and consumer health products.
Johnson & Johnson presents a balanced investment profile, appealing to investors seeking a combination of growth and dividends. The company has a stable dividend yield, indicating a commitment to returning value to shareholders. Its diversified business segments provide resilience against market fluctuations, making it suitable for medium to long-term investment horizons.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-02 | Hold | Buy | Stable dividend, but recent performance shows weakness. |
| 2026-07-31 | Buy | Hold | Weak momentum and fundamentals raise uncertainty. |
| 2026-07-24 | Hold | Buy | Stable dividend, moderate growth, watch for earnings recovery. |
| 2026-07-16 | Buy | Hold | Weak momentum and fundamentals suggest caution. |
| 2026-06-27 | Hold | Buy | Strong momentum and solid fundamentals support growth potential. |
| 2026-06-19 | Buy | Hold | Weak momentum and fundamentals raise uncertainty. |
| 2026-06-10 | Hold | Buy | Strong momentum and solid dividend yield support growth. |
| 2026-05-30 | Buy | Hold | Weak momentum and fundamentals raise uncertainty. |
| 2026-05-22 | Hold | Buy | Stable dividends, but mixed momentum signals present uncertainty. |
| 2026-05-08 | — | Hold | Weak momentum and fundamentals suggest caution. |
| 2026-05-08 | Buy | Buy | Компания имеет стабильные финансовые показатели и дивидендную доходность, однако недавнее снижение цен акций и отрицательная динамика выручки могут указывать на краткосрочные риски. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-02 | UBS | Update | — → 320 | 271.19 |
| 2026-08-06 | Guggenheim | Target Raised | 270 → 287 | 257.59 |
| 2026-08-03 | Raymond James | Target Raised | — → 280 | 254.4472 |
| 2026-08-03 | Wells Fargo | Target Raised | 272 → 282 | 256.35 |
| 2026-07-29 | Argus Research | Target Raised | 290 → 300 | 266.13 |
| 2026-07-16 | Johnson Rice | Rating Upgraded | — → 280 | 249.755 |
| 2026-07-16 | Scotiabank | Target Raised | 265 → 305 | 248.94501 |
| 2026-07-16 | Raymond James | Target Raised | 258 → 265 | 250.5 |
| 2026-07-16 | Johnson Rice | Target Raised | — → 261 | 250.49001 |
| 2026-07-16 | Goldman Sachs | Target Raised | 275 → 282 | 247.02 |
| 2026-07-16 | Morgan Stanley | Target Raised | 284 → 294 | 247.02 |
| 2026-07-16 | Wells Fargo | Target Raised | 263 → 272 | 247.02 |
| 2026-07-15 | Stifel Nicolaus | Target Raised | 250 → 260 | 247.02 |
| 2026-07-13 | RBC Capital | Target Raised | 265 → 287 | 257.605 |
| 2026-07-08 | Morgan Stanley | Target Raised | 283 → 284 | 267.24 |
| 2026-07-06 | HSBC | Target Raised | 280 → 290 | 258.655 |
| 2026-06-26 | Guggenheim | Target Raised | 266 → 270 | 253.56 |
| 2026-06-26 | Johnson Rice | Target Raised | — → 270 | 253.29 |
| 2026-05-13 | Leerink Partners | Rating Upgraded | — → 265 | 224.26 |
| 2026-04-20 | Guggenheim | Target Raised | 244 → 266 | 232.71 |
| 2026-04-15 | Morgan Stanley | Target Raised | 267 → 283 | 239.66 |
| 2026-04-15 | RBC Capital | Target Raised | 255 → 265 | 240.1 |
| 2026-04-15 | Stifel Nicolaus | Target Raised | 220 → 250 | 240.1 |
| 2026-04-15 | Barclays | Target Raised | 234 → 255 | 240.1 |
| 2026-04-10 | Morgan Stanley | Target Raised | 262 → 267 | 239.5 |
| 2026-03-18 | Morgan Stanley | Update | — → 253 | 237.19 |
| 2026-02-03 | RBC Capital | Target Raised | 240 → 255 | 233.35 |
| 2026-01-28 | Morgan Stanley | Update | — → 262 | 224.44 |
